Wells Fargo raised the firm’s price target on Kyverna Therapeutics (KYTX) to $33 from $31 and keeps an Overweight rating on the shares. The firm notes that mivocabtagene-autoleucel’s stiff person syndrome data is in line with its bull case and it believes shares should trade up into the mid-teens on the data. Wells thinks mivocabtagene-autoleucel could potentially benefit from priority review/CNPV given the high unmet need in stiff person syndrome.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
- Closing Bell Movers: Ford nudges higher raised outlook, EV charge
- Kyverna Therapeutics offers to sell $100M in common stock
- Kyverna Therapeutics’ Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating
- Leerink raises Kyverna price target, says KYSA-8 study results transformative